|
1
|
Kikuchi J, Ohhara Y, Takada K, Tanabe H,
Hatanaka K, Amano T, Hatanaka KC, Hatanaka Y, Mitamura T, Kato M,
et al: Clinical significance of comprehensive genomic profiling
tests covered by public insurance in patients with advanced solid
cancers in Hokkaido, Japan. Jpn J Clin Oncol. 51:753–761.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
de Bono J, Mateo J, Fizazi K, Saad F,
Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, et al:
Olaparib for metastatic castration-resistant prostate cancer. N
Engl J Med. 382:2091–2102. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Saad F, Clarke NW, Oya M, Shore N,
Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, et al:
Olaparib plus abiraterone versus placebo plus abiraterone in
metastatic castration-resistant prostate cancer (PROpel): Final
prespecified overall survival results of a randomised,
double-blind, phase 3 trial. Lancet Oncol. 24:1094–1108.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Agarwal N, Azad AA, Carles J, Fay AP,
Matsubara N, Heinrich D, Szczylik C, Giorgi UD, Joung JY, Fong PCC,
et al: Talazoparib plus enzalutamide in men with first-line
metastatic castration-resistant prostate cancer (TALAPRO-2): A
randomised, placebo-controlled, phase 3 trial. Lancet. 402:291–303.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sweeney CJ, Chen YH, Carducci M, Liu G,
Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et
al: Chemohormonal therapy in metastatic Hormone-Sensitive prostate
cancer. N Engl J Med. 373:737–746. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Clinical practice guidance for
next-generation sequencing in cancer diagnosis and treatment
(edition 2.1). Available from: http://www.jca.gr.jp/researcher/topics/2020/files/20200518.pdf
Accessed June 27, 2023.
|
|
7
|
Koguchi D, Tsumura H, Tabata K, Shimura S,
Satoh T, Ikeda M, Watanabe A, Yoshida T, Sasaki J, Matsumoto K and
Iwamura M: Real-world data on the comprehensive genetic profiling
test for Japanese patients with metastatic Castration-resistant
prostate cancer. Jpn J Clin Oncol. 53:569–576. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Clinical Practice Guidance for Prostate
Cancer. Available from: https://jua.members-web.com/topics1/uploads/attach/topic.
Accessed December 1, 2023.
|
|
9
|
Scher HI, Morris MJ, Stadler WM, Higano C,
Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et
al: Trial design and objectives for Castration-resistant prostate
cancer: Updated recommendations from the prostate cancer clinical
trials working group 3. J Clin Oncol. 34:1402–1418. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Le Tourneau C, Delord JP, Goncalves A,
Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA,
Mauborgne C, et al: Molecularly targeted therapy based on tumour
molecular profiling versus conventional therapy for advanced cancer
(SHIVA): A multicentre, open-label, proof-of-concept, randomised,
controlled phase 2 trial. Lancet Oncol. 16:1324–1334.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Belin L, Kamal M, Mauborgne C, Plancher C,
Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N,
et al: Randomized phase II trial comparing molecularly targeted
therapy based on tumor molecular profiling versus conventional
therapy in patients with refractory cancer: Cross-over analysis
from the SHIVA trial. Ann Oncol. 28:590–596. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Krämer A, Bochtler T, Pauli C, Shiu KK,
Cook N, Janoski de Menezes J, Pazo-Cid RA, Losa F, Robbrecht DGJ,
Tomášek J, et al: Molecularly guided therapy versus chemotherapy
after disease control in unfavourable cancer of unknown primary
(CUPISCO): An open-label, randomised, phase 2 study. Lancet.
404:527–539. 2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sandhu S, Moore CM, Chiong E, Beltran H,
Bristow RG and Williams SG: Prostate cancer. Lancet. 398:1075–1090.
2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mateo J, Seed G, Bertan C, Rescigno P,
Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B,
Clarke M, et al: Genomics of lethal prostate cancer at diagnosis
and castration resistance. J Clin Invest. 30:1743–1751.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Swisher EM, Kristeleit RS, Oza AM, Tinker
AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C,
O'Malley DM, et al: Characterization of patients with long-term
responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol. 163:490–497. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Buonaiuto R, Neola G, Caltavituro A,
Longobardi A, Mangiacotti FP, Cefaliello A, Lamia MR, Pepe F,
Ventriglia J, Malapelle U, et al: Efficacy of PARP inhibitors in
advanced high-grade serous ovarian cancer according to BRCA domain
mutations and mutation type. Front Oncol.
14(1412807)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lenis AT, Ravichandran V, Brown S, Alam
SM, Katims A, Truong H, Reisz PA, Vasselman S, Nweji B, Autio KA,
et al: Microsatellite instability, tumor mutational burden, and
response to immune checkpoint blockade in patients with prostate
cancer. Clin Cancer Res. 30:3894–3903. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Abida W, Armenia J, Gopalan A, Brennan R,
Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, et al:
Prospective genomic profiling of prostate cancer across disease
states reveals germline and somatic alterations that may affect
clinical decision making. JCO Precis Oncol.
2017(PO.17.00029)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Barata P, Agarwal N, Nussenzveig R,
Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J,
Babiker H, et al: Clinical activity of pembrolizumab in metastatic
prostate cancer with microsatellite instability high (MSI-H)
detected by circulating tumor DNA. J Immunother Cancer.
8(e001065)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Landi L, D'Inca F, Gelibter A, Chiari R,
Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta
D, et al: Bone metastases and immunotherapy in patients with
advanced non-small-cell lung cancer. J Immunother Cancer.
7(316)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yang K, Li J, Bai C, Sun Z and Zhao L:
Efficacy of immune checkpoint inhibitors in Non-small-cell lung
cancer patients with different metastatic sites: A systematic
review and meta-analysis. Front Oncol. 10(1098)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhu YJ, Chang XS, Zhou R, Chen YD, Ma HC,
Xiao ZZ, Qu X, Liu YH, Liu LR, Li Y, et al: Bone metastasis
attenuates efficacy of immune checkpoint inhibitors and displays
‘cold’ immune characteristics in Non-small cell lung cancer. Lung
Cancer. 166:189–196. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hong DS, DuBois SG, Kummar S, Farago AF,
Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin
JD, Federman N, et al: Larotrectinib in patients with TRK
fusion-positive solid tumours: A pooled analysis of three phase 1/2
clinical trials. Lancet Oncol. 21:531–540. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Doebele RC, Drilon A, Paz-Ares L, Siena S,
Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al:
Entrectinib in patients with advanced or metastatic NTRK
fusion-positive solid tumours: Integrated analysis of three phase
1-2 trials. Lancet Oncol. 21:271–282. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shimoi T, Sunami K, Tahara M, Nishiwaki S,
Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, et
al: Dabrafenib and trametinib administration in patients with BRAF
V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE,
NCCH1901): A multicentre, open-label, and single-arm phase II
trial. EClinicalMedicine. 69(102447)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Subbiah V, Wolf J, Konda B, Kang H, Spira
A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, et al:
Tumour-agnostic efficacy and safety of selpercatinib in patients
with RET fusion-positive solid tumours other than lung or thyroid
tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial.
Lancet Oncol. 23:1261–1273. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Owsley J, Stein MK, Porter J, In GK, Salem
M, O'Day S, Elliott A, Poorman K, Gibney G and VanderWalde A:
Prevalence of class I-III BRAF mutations among 114,662 cancer
patients in a large genomic database. Exp Biol Med (Maywood).
246:31–39. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ueki A, Yoshida R, Kosaka T and
Matsubayashi H: Clinical risk management of breast, ovarian,
pancreatic, and prostatic cancers for BRCA1/2 variant carriers in
Japan. J Hum Genet. 68:517–526. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Page EC, Bancroft EK, Brook MN, Assel M,
Al Battat MH, Thomas S, Taylor N, Chamberlain A, Pope J, Ni
Raghallaigh H, et al: Interim results from the IMPACT study:
Evidence for prostate-specific antigen screening in BRCA2 mutation
carriers. Eur Urol. 76:831–842. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marchetti C, De Felice F, Palaia I,
Perniola G, Musella A, Musio D, Muzii L, Tombolini V and Panici PB:
Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on
ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2
mutation carriers. BMC Womens Health. 14(150)2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Usui Y, Taniyama Y, Endo M, Koyanagi YN,
Kasugai Y, Oze I, Ito H, Imoto I, Tanaka T, Tajika M, et al:
Helicobacter pylori, Homologous-recombination genes, and gastric
cancer. N Engl J Med. 388:1181–1190. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lubinski J, Kotsopoulos J, Moller P, Pal
T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, et al:
MRI surveillance and breast cancer mortality in women with BRCA1
and BRCA2 sequence variations. JAMA Oncol. 10:493–499.
2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pritchard CC, Mateo J, Walsh MF, De Sarkar
N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R,
et al: Inherited DNA-repair gene mutations in men with metastatic
prostate cancer. N Engl J Med. 375:443–453. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kawamura M, Shirota H, Niihori T, Komine
K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Kikuchi A, Tada
H, et al: Management of patients with presumed germline pathogenic
variant from tumor-only genomic sequencing: A retrospective
analysis at a single facility. J Hum Genet. 68:399–408.
2023.PubMed/NCBI View Article : Google Scholar
|
